High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?

BACKGROUND: Globally 3.9% of new and 21% of re-treatment tuberculosis (TB) cases are multidrug-resistant or rifampicin-resistant (MDR/RR), which is often interpreted as evidence that drug resistance results mainly from poor treatment adherence. This study aims to assess the respective contributions...

Descripción completa

Detalles Bibliográficos
Autores principales: Ragonnet, Romain, Trauer, James M., Denholm, Justin T., Marais, Ben J., McBryde, Emma S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217596/
https://www.ncbi.nlm.nih.gov/pubmed/28061832
http://dx.doi.org/10.1186/s12879-016-2171-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5217596/
https://www.ncbi.nlm.nih.gov/pubmed/28061832
http://dx.doi.org/10.1186/s12879-016-2171-1

Ejemplares similares